Holen Sie sich die Stockscreener-App
13.96
1.82%
0.25
Handel nachbörslich:
13.96
Schlusskurs vom Vortag:
$13.71
Offen:
$13.84
24-Stunden-Volumen:
431.82K
Relative Volume:
0.80
Marktkapitalisierung:
$566.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-2.7212
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
-3.12%
1M Leistung:
-3.32%
6M Leistung:
+37.54%
1J Leistung:
-68.71%
1-Tages-Spanne:
$13.79
$13.98
1-Wochen-Bereich:
$13.13
$14.26
52-Wochen-Spanne:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Vergleichen Sie KROS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
13.96 | 556.84M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
William Blair Issues Pessimistic Outlook for KROS Earnings - MarketBeat
XTX Topco Ltd Invests $490,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $20.00 by Analysts at HC Wainwright - MarketBeat
Leerink Partnrs Brokers Reduce Earnings Estimates for KROS - MarketBeat
Leerink Partners Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Keros Therapeutics stock price target lowered to $20 at H.C. Wainwright - Investing.com Canada
Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics - TipRanks
Keros prioritizes KER-065, pulls plug on cibotercept - The Pharma Letter
Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks - TipRanks
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $15 - 富途牛牛
Keros Therapeutics to discontinue cibotercept, announces COO departure - TipRanks
Keros Therapeutics, Inc. (NASDAQ:KROS) Holdings Raised by Federated Hermes Inc. - MarketBeat
Keros Therapeutics: Strategic Shift and Organizational Changes Prompt Hold Rating - TipRanks
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Keros Therapeutics Announces Strategic Realignment and Leadership Changes - TipRanks
Keros Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Keros discontinues cibotercept development, announces leadership changes By Investing.com - Investing.com South Africa
Keros Therapeutics Announces Discontinuation of Cibotercept Development and Leadership Changes for Strategic Realignment - Quiver Quantitative
Keros Transforms Pipeline: Focuses All Resources on Promising DMD Drug KER-065 as Phase 2 Trial Approaches - Stock Titan
Keros Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewswire
Is it the right time to buy Keros Therapeutics Inc. stockGet timely alerts on top market movers - Jammu Links News
Published on: 2025-08-03 17:03:57 - Jammu Links News
Keros Therapeutics Inc. Stock Analysis and ForecastCapitalize on momentum-driven investment opportunities - Jammu Links News
How does Keros Therapeutics Inc. compare to its industry peersBuild wealth faster with consistent investment plans - Jammu Links News
What are analysts’ price targets for Keros Therapeutics Inc. in the next 12 monthsAchieve breakthrough profits with expert advice - Jammu Links News
What are Keros Therapeutics Inc. company’s key revenue driversUnlock exclusive stock market forecasts - Jammu Links News
What are the technical indicators suggesting about Keros Therapeutics Inc.Unlock powerful portfolio optimization tools - Jammu Links News
Keros Therapeutics (KROS) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
What catalysts could drive Keros Therapeutics Inc. stock higher in 2025Unlock powerful portfolio management tools - jammulinksnews.com
How strong is Keros Therapeutics Inc. company’s balance sheetGain the edge with real-time market data - Jammu Links News
Is Keros Therapeutics Inc. stock overvalued or undervaluedExceptional market performance - Jammu Links News
How volatile is Keros Therapeutics Inc. stock compared to the marketRapid wealth creation - Jammu Links News
Why is Keros Therapeutics Inc. stock attracting strong analyst attentionPowerful market insights - Jammu Links News
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Price Target from Analysts - MarketBeat
Does Keros Therapeutics Inc. stock perform well during market downturnsEarnings Report Growth Plan For Smart Trading - Jammu Links News
What is the risk reward ratio of investing in Keros Therapeutics Inc. stockTop Growth Tips For Consistent Profits - Jammu Links News
Corton Capital Inc. Invests $186,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Will Keros Therapeutics Inc. continue its uptrendExit Ready Momentum Stock Watchlist Expanded - metal.it
Can Keros Therapeutics Inc. Outperform Peers After Recent PullbackEarly Entry Tips With Low Risk Zone Shared - metal.it
Bollinger Bands Show Potential Breakout in Keros Therapeutics Inc.AI Screening for Swing Trade Picks Finds Momentum - metal.it
What makes Keros Therapeutics Inc. stock price move sharplyPre Market Trend Scanner From AI Tools - Jammu Links News
Published on: 2025-07-29 02:02:32 - beatles.ru
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):